Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
- PMID: 17685736
- DOI: 10.4088/jcp.v68n0706
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
Abstract
Objectives: To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression.
Method: This multiple-phase study, entitled "Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years" (PREVENT), was conducted from December 2000 through July 2005 in patients with recurrent unipolar depression (DSM-IV) who were initially randomly assigned to double-blind treatment with venlafaxine ER (75 mg/day to 300 mg/day) or fluoxetine (20 mg/day to 60 mg/day) for 10 weeks of acute treatment. Responders then received 6 months of continuation treatment. Those who remained responders were then enrolled into a 12-month maintenance period. Venlafaxine ER responders were randomly assigned to receive double-blind treatment with venlafaxine ER or placebo. Fluoxetine responders were not randomly assigned but continued taking fluoxetine in order to maintain the blind during the maintenance study. Time to recurrence of depression (17-item Hamilton Rating Scale for Depression total score > 12 and < 50% reduction from acute phase baseline) with venlafaxine ER versus that of placebo were compared.
Results: The efficacy evaluable sample consisted of 129 patients in each group. The mean daily dose of venlafaxine ER was 224.7 mg (SD = 66.7). The cumulative probability of recurrence through 12 months, based on the primary definition, was 23.1% (95% CI = 15.3 to 30.9) for venlafaxine ER and 42.0% (95% CI = 31.8 to 52.2) for placebo (p = .005, log-rank test).
Conclusion: Patients who had been successfully treated with venlafaxine ER during acute and continuation therapy were significantly less likely to experience recurrence with venlafaxine ER than with placebo over a 12-month maintenance treatment period.
Clinical trials registration: ClinicalTrials.gov identifier NCT00046020.
Comment in
-
Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions?J Clin Psychiatry. 2008 May;69(5):865-6; author reply 866. doi: 10.4088/jcp.v69n0522e. J Clin Psychiatry. 2008. PMID: 18681767 No abstract available.
Similar articles
-
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.J Clin Psychiatry. 2014 Jan;75(1):62-8. doi: 10.4088/JCP.12m07841. J Clin Psychiatry. 2014. PMID: 24345717 Clinical Trial.
-
Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2. Int Clin Psychopharmacol. 2008. PMID: 18408525 Clinical Trial.
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.J Clin Psychiatry. 2007 Aug;68(8):1246-56. doi: 10.4088/jcp.v68n0812. J Clin Psychiatry. 2007. PMID: 17854250 Clinical Trial.
-
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?J Clin Psychiatry. 2004;65 Suppl 17:29-33. J Clin Psychiatry. 2004. PMID: 15600379 Review.
-
Venlafaxine extended-release: a review of its use in the management of major depression.CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review.
Cited by
-
An assessment of the reporting of tapering methods in antidepressant discontinuation trials using the TIDieR checklist.Int J Clin Pharm. 2023 Oct;45(5):1074-1087. doi: 10.1007/s11096-023-01602-z. Epub 2023 Jun 3. Int J Clin Pharm. 2023. PMID: 37269440 Free PMC article.
-
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013495. doi: 10.1002/14651858.CD013495.pub2. Cochrane Database Syst Rev. 2021. PMID: 33886130 Free PMC article.
-
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis.Mol Psychiatry. 2021 Jan;26(1):118-133. doi: 10.1038/s41380-020-0843-0. Epub 2020 Jul 23. Mol Psychiatry. 2021. PMID: 32704061 Free PMC article.
-
Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II.Int J Neuropsychopharmacol. 2017 Mar 1;20(3):281-284. doi: 10.1093/ijnp/pyw092. Int J Neuropsychopharmacol. 2017. PMID: 28003313 Free PMC article. No abstract available.
-
Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.Prim Care Companion CNS Disord. 2015 Aug 27;17(4):10.4088/PCC.14m01711. doi: 10.4088/PCC.14m01711. eCollection 2015. Prim Care Companion CNS Disord. 2015. PMID: 26693033 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical